ASX:UBI

Universal Biosensors (UBI) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
10,006 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
8.55%
Price Target
N/A
UBI stock logo

About Universal Biosensors Stock (ASX:UBI)

Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices used in healthcare (point-of-care), wine, food, and agriculture industries in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO2, malic acid, glucose, fructose, total acid, and titratable acidity. It also offers non-diagnostic laboratory services and performs coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a test strip and a meter to be used for the detection and monitoring of diabetes in non-humans. Universal Biosensors, Inc. was incorporated in 2001 and is based in Rowville, Australia.

UBI Stock News Headlines

The asset beating inflation by 4x
"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.
UBI Business School
The asset beating inflation by 4x
"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.
Universal Basic Income (UBI)
Universal Biosensors, Inc.'s (ASX:UBI) Profit Outlook
Tencent Deal Cools Investors’ Hopes of Ubisoft Takeover
Tencent Looks Abroad to Level Up
Universal Biosensors Inc
See More Headlines
Receive UBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Universal Biosensors and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/30/2019
Today
5/05/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Devices
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
80
Year Founded
N/A

Profitability

Net Income
$-6,740,000.00
Net Margins
-101.64%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.63 million
Book Value
A$0.09 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.92
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. John Stewart Sharman B Ec (Age 58)
    BECON, C.A., CA, M.App.Fin, Chief Executive Officer
    Comp: $843.3k
  • Mr. Salesh Balak B.A. (Age 55)
    BA, C.A., CA, CFO & Company Secretary
    Comp: $325.61k
  • Mr. Nicholas Bliesner
    Head of Operations
  • Mr. Steven Burgess
    Head of Sales & Marketing
  • Mr. Luke Cossins B.Sc.
    M.B.A., Head of Research & Development
  • Ms. Ann Chew B.Com.
    CPA, CIA, Head of People Strategy & Culture

UBI Stock Analysis - Frequently Asked Questions

How were Universal Biosensors' earnings last quarter?

Universal Biosensors, Inc. (ASX:UBI) issued its earnings results on Tuesday, April, 30th. The company reported ($0.01) earnings per share (EPS) for the quarter. Universal Biosensors had a negative trailing twelve-month return on equity of 29.57% and a negative net margin of 101.64%.

This page (ASX:UBI) was last updated on 5/5/2024 by MarketBeat.com Staff

From Our Partners